Policy Recommendations for Strengthening the Accelerated Approval Program for Oncology Drugs
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Policy
Market-Level Changes and New Hospital Payment Models in Health Care
Testimony: Delivered to Pennsylvania House of Representatives Subcommittee on Health Facilities
Print:
On October 4, 2023, Paula Chatterjee, MD, MPH, the LDI Director of Health Equity Research testified in front of the Pennsylvania House of Representatives Subcommittee on Health Facilities about the unprecedented market-level changes that have occurred in health care over the past decade, and the latest new hospital payment models designed to address the consequences of those changes. Her remarks focused on federal and state programs designed to to support financially stressed hospitals, particularly those in rural areas.
More on Policy at LDI
Estimated Overdose Deaths Due to the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Health Impacts of SNAP Provisions in the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Projected Mortality Impacts of the Budget Reconciliation Bill
Research Memo: Response to Request for Technical Assistance
Loss of Subsidized Drug Coverage and Mortality Following Medicaid Disenrollment: Translating our Findings and Implications for Medicaid Policy
Research Memo: Supplement to Response to Request for Technical Assistance
Medicaid’s Role in Health and the Health Care Landscape: Key Takeaways from LDI Researchers
Research Memo: Delivered to Staff of U.S. Senate Committee on Finance